Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19607662 | 0.83 | MEN1 (0.42) | MEN1KMT2AKCNH2OGAOXTR | |
| SCHEMBL9942876 | 0.82 | HRH3 (0.41) | MEN1KMT2AHRH3KCNH2OGA | |
| SCHEMBL22957028 | 0.82 | MEN1 (0.41) | MEN1KMT2AKCNH2OGAOXTR | |
| SCHEMBL109928 | 0.82 | MEN1 (0.41) | MEN1KMT2AHRH3KCNH2OGA | |
| SCHEMBL16059112 | 0.79 | HSD17B3 (0.41) | MEN1KMT2AHRH3KCNH2OGA | |
| SCHEMBL16380576 | 0.79 | MEN1 (0.40) | MEN1KMT2AKCNH2OGACYP2D6 | |
| SCHEMBL15284926 | 0.79 | OXTR (0.39) | KMT2AOXTRHSD17B3MAOAMAOB | |
| SCHEMBL21014434 | 0.78 | MEN1 (0.35) | MEN1KMT2AOGAOXTRHSD17B3 | |
| SCHEMBL20010323 | 0.76 | RIPK1 (0.42) | HRH3KCNH2OGACYP2D6 | |
| SCHEMBL1101990 | 0.75 | MEN1 (0.55) | MEN1KMT2AHRH3KCNH2OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117872-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-09-14 | — | — | US | disclosed |
| US-10913725-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-02-09 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160002247-A1 | 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913725-B2 | Oxazine compound, composition and cured product | PSMB5, KDM5A, CUL5 | MEN1 2353/4885KMT2A 548/4885HRH3 2524/4885 |
| US-20160002247-A1 | 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | ENPP2, UACA, IAPP | MEN1 1396/4885KMT2A 2306/4885HRH3 3599/4885 |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | MEN1 4470/4885KMT2A 2047/4885HRH3 4398/4885 |
| US-11117872-B2 | Oxazine compound, composition and cured product | KDM5A, WDR5, RNF5 | MEN1 2503/4885KMT2A 632/4885HRH3 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.